FCRL3/FcRH3 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-09272
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Concentration
0.5 mg/ml
Product Specifications
Immunogen
The immunogen is a synthetic peptide directed towards the middle region of Human FCRL3/FcRH3. Peptide sequence RGSSLSDAVHVEFSPDWLILQALHPVFEGDNVILRCQGKDNKNTHQKVYY
Clonality
Polyclonal
Host
Rabbit
Theoretical MW
21 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for FCRL3/FcRH3 Antibody
Western Blot: FCRL3/FcRH3 Antibody [NBP3-09272]
Western Blot: FCRL3/FcRH3 Antibody [NBP3-09272] - Western blot analysis of FCRL3/FcRH3 in OVCAR-3 Whole cell lysates. Antibody dilution at 1.0ug/mlApplications for FCRL3/FcRH3 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: FCRL3/FcRH3
Long Name
Fc Receptor-like 3
Alternate Names
CD307c, FcRH3, IFGP3, IRTA3, SPAP2
Gene Symbol
FCRL3
Additional FCRL3/FcRH3 Products
Product Specific Notices for FCRL3/FcRH3 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...